Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients.
This study aimed to evaluate the outcome following myeloablative allogeneic hematopoietic stem cell transplantation (SCT) among patients older than 50 yr of age. A total of 215 patients with a median age of 57 yr underwent allogeneic hematopoietic SCT for early (41%) or advanced (59%) hematologic malignancies. After a median follow-up of 36 months a 10-yr survival estimate of 56 +/- 6% could be assessed for patients in early disease stages while patients with advanced diseases showed a significantly decreased survival probability of 31 +/- 5% (p < 0.0002). Transplant related mortality (TRM) at day 100 and 365 post-transplant was 13% and 30% for early but increased to 21% and 49% for advanced disease stages. As major determinants of TRM advanced disease stage (p < 0.0001) and occurrence of grades II-IV graft-vs.-host disease (GVHD) (p < 0.0001) were identified. These results show that hematopoietic SCT following myeloablative conditioning is also applicable to elderly patients whereas disease stage and high-grade GVHD represent the essential prognostic factors for outcome.
Ditschkowski
M
M
Department of bone marrow transplantation, University Hospital of Essen, Hufelandstr, Essen, Germany. markus.ditschkowski@uni-essen.de
Elmaagacli
A H
AH
Trenschel
R
R
Steckel
N K
NK
Koldehoff
M
M
Beelen
D W
DW
D000368:Aged; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000601:surgery*; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000601:surgery*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000601:surgery; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000601:surgery*; D009196:Myeloproliferative Disorders / Q000401:mortality / Q000601:surgery*; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome